Actinium Pharmaceuticals Inc. (ATNM) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Actinium Pharmaceuticals ...

    AMEX: ATNM · Real-Time Price · USD
    1.59
    0.00 (0.00%)
    At close: Sep 26, 2025, 3:59 PM
    1.60
    0.31%
    After-hours: Sep 26, 2025, 06:28 PM EDT

    Actinium Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 81K 1.03M 1.14M
    Cost of Revenue
    		 811K 790K 699K 524K
    Gross Profit
    		 -811K 81K 1.03M 1.14M
    Operating Income
    		 -42.12M -51.92M -34.1M -24.96M
    Interest Income
    		 3.88M 3.1M 1.09M 190K
    Pretax Income
    		 -38.24M -48.82M -33.02M -24.77M
    Net Income
    		 -38.24M -48.82M -33.02M -24.77M
    Selling & General & Admin
    		 12.08M 13.33M 12M 8.08M
    Research & Development
    		 30.05M 38.67M 23.14M 18.03M
    Other Expenses
    		 -811K n/a n/a n/a
    Operating Expenses
    		 41.31M 52M 35.13M 26.11M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 42.12M 52M 35.13M 26.11M
    Income Tax Expense
    		 n/a n/a n/a -190K
    Shares Outstanding (Basic)
    		 30.07M 26.6M 24.14M 20.57M
    Shares Outstanding (Diluted)
    		 30.07M 26.6M 24.14M 20.57M
    EPS (Basic)
    		 -1.27 -1.83 -1.37 -1.2
    EPS (Diluted)
    		 -1.27 -1.83 -1.37 -1.2
    EBITDA
    		 -37.43M -51.13M -33.41M -24.44M
    EBIT
    		 -38.24M -51.92M -34.1M -24.96M
    Depreciation & Amortization
    		 811K 790K 699K 524K

    Add to Watchlist